Dr. Tanya Siddiqi, MD

Dr. Siddiqi practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Siddiqi's NPI, 1467408948, was assigned on May 26, 2006. Dr. Siddiqi graduated from Aga Khan Medical College in 2000. Dr. Siddiqi holds California license A107162.

Dr. Siddiqi's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Siddiqi's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Siddiqi to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Siddiqi practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Siddiqi's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Siddiqi is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Siddiqi's licenses on file in 2 states: California and Massachusetts.

Dmand AI lists chronic anemia, chronic leukemia, immune deficiency disease, lung cancer, lymphoma, multiple myeloma and purpura and thrombocytopenia among the conditions Dr. Siddiqi treats.

CMS data shows 1,177 Medicare services from Dr. Siddiqi across 5 procedure codes in 2024, for 277 Medicare patients. Medicare paid $104,800 for them. Every service was in an office.

CMS counts 277 Medicare patients who saw Dr. Siddiqi in 2024. The largest group is 65 to 74, with 132 patients. 75% of them have high cholesterol, and 65% have high blood pressure. 7% are also on Medicaid. Their average risk score is 2.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Siddiqi's median patient age at 72, with 49% women.

In 2024, Dr. Siddiqi wrote 445 Medicare Part D claims for 90 patients. CMS names the drug for 314 of them, across 8 drugs with 11 or more claims each, at $2,910,719 in total drug cost. In 2023, CMS named 284 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Siddiqi for performance year 2024, reported as part of a group. Dr. Siddiqi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Siddiqi as offering telehealth.

Dmand AI links 29 papers to Dr. Siddiqi, published from 2023 to 2025. 2024 was the busiest year, with 9. The most frequent topics are Leukemia, Lymphocytic, Chronic, B-Cell, Immunotherapy, Adoptive and Lymphoma, Large B-Cell, Diffuse. Dr. Siddiqi has published most often in Blood Adv. Dr. Siddiqi's most frequent co-authors are Caron Alyce Jacobson, MD, Matthew Alexander Lunning, DO and William G. Wierda, MD, PhD.

CMS Open Payments shows 269 general payments to Dr. Siddiqi from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 39% of the total. AstraZeneca Pharmaceuticals LP paid the most, $67,527. It also lists 2 research payments totaling $106 from 2016 to 2019.

Dr. Siddiqi graduated from Aga Khan Medical College in 2000.

Dr. Siddiqi is in network with 7 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.